GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » OncoCyte Corp (NAS:OCX) » Definitions » Price-to-Operating-Cash-Flow

OncoCyte (OncoCyte) Price-to-Operating-Cash-Flow : (As of Apr. 26, 2024)


View and export this data going back to 2015. Start your Free Trial

What is OncoCyte Price-to-Operating-Cash-Flow?

As of today (2024-04-26), OncoCyte's share price is $2.48. OncoCyte's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.29. Hence, OncoCyte's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for OncoCyte's Price-to-Operating-Cash-Flow or its related term are showing as below:

OCX's Price-to-Operating-Cash-Flow is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 19.22
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

OncoCyte's Cash Flow from Operations per share for the three months ended in Dec. 2023 was $-0.55. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.29.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 27.30% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 9.00% per year. During the past 10 years, the average Operating Cash Flow per Share Growth Rate was -7.20% per year.

During the past 11 years, OncoCyte's highest 3-Year average Operating Cash Flow per Share Growth Rate was 27.30% per year. The lowest was -37.40% per year. And the median was -10.10% per year.


OncoCyte Price-to-Operating-Cash-Flow Historical Data

The historical data trend for OncoCyte's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoCyte Price-to-Operating-Cash-Flow Chart

OncoCyte Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

OncoCyte Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of OncoCyte's Price-to-Operating-Cash-Flow

For the Diagnostics & Research subindustry, OncoCyte's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OncoCyte's Price-to-Operating-Cash-Flow Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, OncoCyte's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where OncoCyte's Price-to-Operating-Cash-Flow falls into.



OncoCyte Price-to-Operating-Cash-Flow Calculation

OncoCyte's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio=Share Price/Cash Flow from Operations per share (TTM)
=2.48/-3.292
=

OncoCyte's Share Price of today is $2.48.
OncoCyte's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.29.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio=Market Cap/Cash Flow from Operations

OncoCyte Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of OncoCyte's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


OncoCyte (OncoCyte) Business Description

Traded in Other Exchanges
N/A
Address
15 Cushing, Irvine, CA, USA, 92618
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through the United States.
Executives
John Peter Gutfreund other: Former Director 767 5TH AVENUE, 44TH FLOOR, NEW YORK NY 10153
Alfred D Kingsley director 150 E 57TH STREET, NEW YORK NY 10022
Pura Vida Investments, Llc 10 percent owner 512 W 22ND STREET, 7TH FLOOR, NEW YORK NY 10011
Broadwood Partners Lp 10 percent owner BROADWOOD CAPITAL INC., 142 WEST 57TH STREET, 11TH FLOOR, NEW YORK NY 10019
Andrew Arno director C/O MERRIMAN CURHAN FORD GROUP, INC., 600 CALIFORNIA STREET, 9TH FLOOR, SAN FRANCISCO CA 94108
Josh Riggs officer: Interim CEO 15 CUSHING, IRVINE CA 92618
Lou Silverman director
James Yang Liu officer: Controller, PAO C/O ONCOCYTE CORPORATION, 15 CUSHING, IRVINE CA 92618
Andrew J. Last director 3420 CENTRAL EXPRESSWAY, SANTA CLARA CA 95051
Jennifer L. Carter director C/O DFP SPONSOR LLC, 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Ronald Asbury Andrews director 5791 VAN ALLEN WAY, CARLSBAD CA 92008
Melinda Griffith director 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Anish M. John officer: SVP, Finance, and Interim CFO C/O ONCOCYTE CORPORATION,, 15 CUSHING, IRVINE CA 92618
Li Yu officer: VP Cntrllr/Prncpl Acctng Offcr 120 NEWPORT CENTER DRIVE., NEWPORT BEACH CA 92660
Efrem Kamen 10 percent owner C/O PURA VIDA INVESTMENTS, LLC, 512 W 22ND STREET, 7TH FLOOR, NEW YORK NY 10011